Utilizing advanced imaging modalities, such as CMR, PYP, and PET, to identify hallmark disease features, including TTR-specific uptake or inflammatory mismatch patterns, can inform individualized treatment strategies, including disease-modifying agents for ATTR amyloidosis or immunosuppression for sarcoidosis. This evidence concerns the gene TTR and sarcoidosis.